Wedbush Has Positive Outlook for RARE FY2027 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Stock analysts at Wedbush upped their FY2027 earnings per share estimates for Ultragenyx Pharmaceutical in a report issued on Thursday, January 23rd. Wedbush analyst L. Chico now expects that the biopharmaceutical company will earn $1.05 per share for the year, up from their previous estimate of $1.04. Wedbush has a “Neutral” rating and a $48.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($6.14) per share. Wedbush also issued estimates for Ultragenyx Pharmaceutical’s FY2028 earnings at $1.92 EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, topping analysts’ consensus estimates of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The firm had revenue of $139.49 million during the quarter, compared to analyst estimates of $135.28 million. During the same period last year, the company earned ($2.23) earnings per share. The business’s revenue for the quarter was up 42.3% on a year-over-year basis.

A number of other equities research analysts also recently issued reports on RARE. TD Cowen increased their price objective on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. JPMorgan Chase & Co. lowered their price target on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a research report on Thursday, November 21st. Cantor Fitzgerald restated an “overweight” rating and set a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday. Canaccord Genuity Group reiterated a “buy” rating and issued a $121.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Tuesday, November 12th. Finally, Wells Fargo & Company lifted their price objective on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an “overweight” rating in a report on Friday, December 20th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $92.43.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE stock opened at $44.05 on Friday. Ultragenyx Pharmaceutical has a 52-week low of $37.02 and a 52-week high of $60.37. The company has a market capitalization of $4.07 billion, a PE ratio of -6.81 and a beta of 0.58. The business’s fifty day moving average is $44.56 and its 200 day moving average is $49.62.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, CEO Emil D. Kakkis sold 8,273 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $50.00, for a total transaction of $413,650.00. Following the completion of the sale, the chief executive officer now owns 2,195,712 shares of the company’s stock, valued at $109,785,600. The trade was a 0.38 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 5.80% of the company’s stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of hedge funds have recently modified their holdings of RARE. True Wealth Design LLC bought a new position in Ultragenyx Pharmaceutical in the 3rd quarter worth $43,000. Values First Advisors Inc. purchased a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth approximately $56,000. Wilmington Savings Fund Society FSB purchased a new stake in Ultragenyx Pharmaceutical during the 3rd quarter valued at $83,000. Nomura Asset Management Co. Ltd. purchased a new stake in Ultragenyx Pharmaceutical during the 3rd quarter valued at $93,000. Finally, R Squared Ltd bought a new position in Ultragenyx Pharmaceutical in the 4th quarter valued at $103,000. Institutional investors own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.